Beam Therapeutics Inc BEAM

NAS: BEAM | ISIN: US07373V1052 28/05/2025

16,88 USD (-0,88%)

(-0,88%) 28/05/2025

Grafiek Beam Therapeutics Inc

Grafiek Beam Therapeutics Inc

1 dag1d -0,88%
1 week1w -2,09%
1 maand1m -14,36%
3 maanden3m -35,91%
6 maanden6m -38,33%
1 jaar1j -28,72%
5 jaar5j -33,93%

Beam Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

15 maart 2021 · Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results · Persbericht

15 maart 2021 · Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer · Persbericht

4 maart 2021 · Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference · Persbericht

23 februari 2021 · Beam Therapeutics Announces Acquisition of Guide Therapeutics · Persbericht

19 januari 2021 · Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors · Persbericht

11 januari 2021 · Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors · Persbericht

5 januari 2021 · Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel Beam Therapeutics Inc

Gezondheidstechnologie

Productie van biologische producten

CEO: John M. Evans

Werknemers: 573

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe